Side-by-side · Research reference
GlutathionevsTesamorelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticHUMAN-REVIEWED6/39 cited
BFDA-ApprovedFlagship27/68 cited
Glutathione
Endogenous Tripeptide · Antioxidant
IV · Oral · Inhaled
Tesamorelin
GHRH Analogue · FDA-Approved
SQ · Abdomen · Once Daily
01Mechanism of Action
Parameter
Glutathione
Tesamorelin
Primary target
Intracellular redox systems, glutathione peroxidase, glutathione transferase
Hypothalamic GHRH receptorsEGRIFTA® (tesamorelin for inje 2010
Pathway
Synthesized via glutamate-cysteine ligase (GCL) → γ-glutamylcysteine → glutathione synthetase (GS) → GSH
GHRH → Pituitary GH release → Liver IGF-1 synthesisFalutz 2007
Downstream effect
Reduction of reactive oxygen species, conjugation of electrophiles, maintenance of cellular thiol-disulfide balance, GPX4 activation for lipid peroxide reduction
Increased GH pulsatility, elevated IGF-1, lipolysis of visceral adipose tissueFalutz 2010
Feedback intact?
—
Yes — physiological pulsatility preserved
Origin
Endogenous tripeptide; predominantly synthesized in liver, exported to extracellular space and tissuesTerrell 2025Hecht 2026
Synthetic 44-AA GHRH analogue with trans-3-hexenoic-acid modification for stabilityEGRIFTA® (tesamorelin for inje 2010
02Dosage Protocols
Parameter
Glutathione
Tesamorelin
Endogenous synthesis
Hepatic synthesis ~10 g/day (basal rate)
Tissue-specific; demand-driven upregulation via Nrf2 signaling.
—
Exogenous oral
250–1000 mg/day
Bioavailability limited; gastric hydrolysis reduces systemic uptake.
—
IV supplementation
600–1200 mg (research protocols)
Used in clinical oxidative stress and hepatic detoxification studies.
—
Precursor strategy
N-acetylcysteine (NAC) 600–1200 mg/day
Provides cysteine for endogenous GSH synthesis; bypasses GI degradation.
—
Frequency
—
Once daily (morning or pre-sleep)
Aligns with natural GH pulse.
Duration
—
12–52 weeks
VAT returns within months of stopping.
Reconstitution
—
Sterile water per labeling
Preserved at 2–8 °C after reconstitution.
Timing
—
Empty stomach, pre-sleep preferred
03Metabolic / Fat Loss Evidence
Parameter
Glutathione
Tesamorelin
Primary fat target
—
Visceral adipose tissue (VAT) — abdominal
Effect on lean mass
—
Modest lean mass preservation / slight increase
Effect reversibility
—
VAT returns within months of stopping
Key publication
—
Falutz et al. NEJM 2007 · Falutz JCEM 2010 · FDA approval 2010Falutz 2007Falutz 2010EGRIFTA® (tesamorelin for inje 2010
04Side Effects & Safety
Parameter
Glutathione
Tesamorelin
Oral supplementation
GI discomfort, bloating (mild, dose-dependent)
—
IV administration
Rare hypersensitivity, infusion site reaction
—
Inhalation
Bronchospasm risk in asthma (rare)
—
Tumor metabolism
Extracellular GSH catabolism supplies cysteine to tumors; theoretical concern in active malignancyHecht 2026
—
Injection site reaction
—
Erythema, pruritus, redness (common)
Fluid retention / Edema
—
Peripheral edema, arthralgia, carpal tunnel (GH-axis effect)
IGF-1 elevation
—
Dose-dependent; supraphysiological levels = discontinue
Cancer risk
—
Contraindicated in active malignancy (GH/IGF-1 axis); theoretical tumour growth riskEGRIFTA® (tesamorelin for inje 2010
Antibody formation
—
~50% at 26 weeks; non-neutralising in most; rare hypersensitivity (<1%)Sévigny 2018
GI symptoms
—
Nausea, diarrhea (mild, transient)
Absolute Contraindications
Glutathione
—Tesamorelin
- ·Active malignancy or history of treated cancer
- ·Pregnancy
- ·Hypersensitivity to tesamorelin or mannitol
- ·Disruption of hypothalamic-pituitary axis (trauma, tumour, radiation)
Relative Contraindications
Glutathione
- ·Active malignancy (theoretical cysteine supply risk)Hecht 2026
- ·Severe asthma (inhaled formulations)
Tesamorelin
- ·Untreated diabetes (monitor HbA1c)
- ·Severe carpal tunnel syndrome
- ·Acute critical illness
05Administration Protocol
Parameter
Glutathione
Tesamorelin
1. Oral administration
Capsule or liquid form, 250–1000 mg once daily. Take on empty stomach for improved absorption, though GI hydrolysis limits bioavailability. NAC precursor strategy often preferred.
Add 2.1 mL sterile water to 2 mg lyophilised vial. Roll gently — do not shake. Solution should be clear.
2. Intravenous
Clinical protocols: 600–1200 mg slow infusion over 30–60 minutes. Used for acute oxidative stress, hepatic detoxification support. Administered in medical settings.
Subcutaneous — abdomen preferred. Rotate sites (avoid same spot within 2 cm). Avoid navel and waistband area.
3. Inhaled formulations
Nebulized GSH (research protocols). Monitor for bronchospasm in reactive airway patients. Used experimentally for pulmonary oxidative stress.
Once daily. Preferred: evening, 2–3 hrs post-meal, before sleep — aligns with natural GH secretion pulse.
4. Precursor supplementation
N-acetylcysteine (NAC) 600–1200 mg/day PO. Provides cysteine substrate for endogenous GSH synthesis. Bypasses gastric degradation, preferred for chronic supplementation.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 21 days.
5. Needle
—
27–31G, 4–8 mm insulin syringe. Pinch skin, 45° angle for lean individuals.
06Stack Synergy
Glutathione
— no documented stacks
Tesamorelin
+ Ipamorelin
StrongTesamorelin (GHRH analogue) and ipamorelin (GHRP / ghrelin mimetic) act on two distinct receptor systems to amplify GH release synergistically — GHRH receptor + ghrelin receptor. This dual-axis stimulation produces a more robust, sustained GH pulse than either alone while maintaining physiological pulsatility. Ipamorelin is highly selective with minimal cortisol or prolactin elevation, making it the preferred GHRP pairing.
- Tesamorelin
- 2 mg SQ · evening
- Ipamorelin
- 200–300 mcg SQ · same injection
- Frequency
- Once daily, pre-sleep
- Primary benefit
- Maximal GH pulsatility, fat loss, recovery, sleep quality